Aralez Pharmaceuticals Inc (TSE:ARZ) Scheduled to Post Quarterly Earnings on Wednesday

Aralez Pharmaceuticals Inc (TSE:ARZ) will issue its quarterly earnings data before the market opens on Wednesday, August 9th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.

Aralez Pharmaceuticals Inc (TSE ARZ) opened at 1.50 on Wednesday. Aralez Pharmaceuticals Inc has a 52-week low of $1.46 and a 52-week high of $8.75. The firm’s 50-day moving average price is $1.71 and its 200 day moving average price is $3.03. The firm’s market cap is $98.77 million.

ARZ has been the topic of several recent analyst reports. Chardan Capital reissued a “buy” rating on shares of Aralez Pharmaceuticals in a report on Wednesday, May 17th. Bloom Burton raised Aralez Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Monday, April 10th.

TRADEMARK VIOLATION NOTICE: This article was first posted by [[site]] and is the property of of [[site]]. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at [[permalink]].

In other news, Director Arthur S. Kirsch bought 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were purchased at an average price of C$1.17 per share, with a total value of C$58,500.00. In the last three months, insiders have sold 20,430 shares of company stock worth $26,212.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.